Dewpoint Therapeutics
Biotechnology company pioneering the field of condensate biology, developing therapeutics that target biomolecular condensates - membraneless organelles that regulate cellular processes.
Notes
Dewpoint Therapeutics is a biotechnology company headquartered in Boston with research operations in Dresden, Germany. The company is pioneering the emerging field of condensate biology, which focuses on biomolecular condensates - membraneless organelles formed through liquid-liquid phase separation that regulate critical cellular processes.
Condensates are involved in many biological processes and have been implicated in diseases ranging from cancer to neurodegeneration. Dewpoint is developing therapeutics that can modulate condensate formation and function, opening up new therapeutic targets that were previously considered undruggable.
The company has established partnerships with major pharmaceutical companies including Bayer and Merck to apply its condensate biology platform to various disease areas.
Team
- Arati Ramesh, Ph.D. - CEO
- Richard Young, Ph.D. - Co-founder & Scientific Advisor (MIT Professor, Whitehead Institute)
- Anthony Hyman, Ph.D. - Co-founder & Scientific Advisor (Max Planck Institute of Molecular Cell Biology and Genetics)
Additional Research Findings
- Portfolio company of Polaris Partners
- Founded in 2018
- Dual headquarters: Boston, MA and Dresden, Germany
- Pioneering condensate biology as a therapeutic modality
- Partnership with Bayer on cardiovascular and oncology targets
- Partnership with Merck on neurodegeneration
- Raised over $200 million in funding
- Co-founded by leading scientists from MIT and Max Planck Institute
- Targeting previously undruggable disease mechanisms
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |